Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...

Mitral Valve Prolapse III: Nursing Management

Mitral Valve Prolapse III: Nursing Management

The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...

Gonadal and Placental Hormones

Gonadal and Placental Hormones

The gonads, namely the testes in males and the ovaries in females, are pivotal in producing gonadal hormones that orchestrate the intricate processes of sexual development and reproduction.
In males, testosterone is the primary gonadal androgen. It plays a central role in the maturation of male reproductive organs — the penis and testes. Additionally, testosterone is instrumental in the development of secondary sexual characteristics — a deep voice as well as facial and pubic hair growth — and...

Ovarian Cycle

Ovarian Cycle

The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle length...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Clinical algorithms for the management of intrapartum maternal urine abnormalities.

BJOG : an international journal of obstetrics and gynaecology·2022

Same author

Intrapartum care algorithms for liquor abnormalities: oligohydramnios, meconium, blood and purulent discharge.

BJOG : an international journal of obstetrics and gynaecology·2022

Same author

Constructing evidence-based clinical intrapartum care algorithms for decision-support tools.

BJOG : an international journal of obstetrics and gynaecology·2022

Same author

Randomized controlled trial of topical corticosteroid and home-based narrowband ultraviolet B for active and limited vitiligo: results of the HI-Light Vitiligo Trial.

The British journal of dermatology·2020

Same author

An economic evaluation of the randomized controlled trial of topical corticosteroid and home-based narrowband ultraviolet B for active and limited vitiligo (the HI-Light Vitiligo Trial).

The British journal of dermatology·2020

Same author

A randomised feasibility trial comparing needle fasciotomy with limited fasciectomy treatment for Dupuytren's contractures.

Pilot and feasibility studies·2020

Search research articles

Related Experiment Video

Updated: Jul 19, 2026

Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption

Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption

Published on: July 30, 2016

Progesterone for preventing pre-eclampsia and its complications.

S Meher¹, L Duley

¹The University of Liverpool, Division of Perinatal and Reproductive Medicine, First Floor, Liverpool Women's NHS Foundation Trust, Crown Street, Liverpool, UK. s.meher@liv.ac.uk

The Cochrane Database of Systematic Reviews

|October 21, 2006

Summary

Current evidence is insufficient to support progesterone use for preventing pre-eclampsia. More research is needed to determine its benefits and harms in pregnancy.

Related Experiment Videos

Last Updated: Jul 19, 2026

Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption

Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption

Published on: July 30, 2016

Area of Science:

Obstetrics and Gynecology
Maternal-Fetal Medicine
Pharmacology in Pregnancy

Background:

Historically, progesterone was considered for pre-eclampsia prevention.
Current clinical practice does not utilize progestogens for this purpose.
Assessing the evidence on progesterone's benefits and harms remains relevant.

Purpose of the Study:

To evaluate the efficacy of progesterone in preventing pre-eclampsia and its complications during pregnancy.

Main Methods:

Searched major databases including Cochrane Pregnancy and Childbirth Group's Trials Register, Cochrane Central Register of Controlled Trials, and EMBASE.
Included randomized controlled trials comparing progesterone or progestogens with placebo or no treatment during pregnancy.
Two independent reviewers assessed study eligibility and extracted data.

Main Results:

Two trials with 296 women, of uncertain quality, were included.
Insufficient evidence exists to show differences in pre-eclampsia risk, infant mortality, preterm birth, or congenital defects.
No cases of female infant masculinization were reported.

Conclusions:

Reliable conclusions regarding progesterone's effectiveness in preventing pre-eclampsia cannot be drawn due to insufficient evidence.
Progesterone is not recommended for pre-eclampsia prevention in current clinical practice.
Further trials are unlikely to be a priority without new hypotheses on progesterone's role.